If primary hyperaldosteronism is suspected in this patient, how should the management be altered?

Management Changes When Suspecting Primary Hyperaldosteronism

Yes, suspecting primary hyperaldosteronism fundamentally changes management—you must pursue confirmatory testing and implement subtype-specific treatment that directly targets aldosterone excess, as this offers the potential for surgical cure or highly effective targeted medical therapy that reduces cardiovascular and renal morbidity beyond blood pressure control alone. 1, 2

Immediate Diagnostic Pathway

Step 1: Confirmatory Testing

If screening suggests primary aldosteronism (elevated aldosterone-to-renin ratio), proceed with confirmatory testing using one of these options 1:

• Saline suppression test: 2L IV normal saline over 4 hours (contraindicated in severe uncontrolled hypertension or heart failure)

  • Primary aldosteronism confirmed if post-infusion aldosterone >280 pmol/L
  • Unlikely if <140 pmol/L

• Oral sodium loading: >200 mmol/day sodium for 3 days

  • Primary aldosteronism confirmed if 24-hour urinary aldosterone >33 nmol/day

• Captopril suppression test: 25-50 mg captopril after 1 hour sitting/standing

  • Primary aldosteronism unlikely if aldosterone suppresses >30%

Important exception: Skip confirmatory testing if the patient has resistant hypertension with hypokalemia AND plasma renin activity <0.2 ng/mL/h with aldosterone >15 ng/dL (LC-MS/MS) or >20 ng/dL (immunoassay)—this represents overt biochemical evidence where confirmatory testing risks false negatives 2.

Step 2: Subtype Classification

Once confirmed, differentiate unilateral from bilateral disease 1, 3:

1. CT or MRI of adrenal glands (3mm contiguous cuts)
2. Adrenal venous sampling (AVS) at experienced centers if:
   • Surgery is an option for the patient
   • Imaging shows an adenoma (may be nonfunctional)
   • Need to verify unilateral hypersecretion before surgery

Treatment Algorithm Based on Subtype

For Unilateral Disease (Aldosterone-Producing Adenoma)

Laparoscopic unilateral adrenalectomy is the treatment of choice 1, 4, 3:

• Offers potential cure
• Pretreat 8-10 weeks before surgery to correct metabolic abnormalities and control blood pressure 4
• Critical caveat: Many patients remain hypertensive post-surgery—close follow-up required 1
• Monitor renal function closely after surgery, as treatment may unmask underlying renal disease with increased creatinine 1

For Bilateral Disease or Non-Surgical Candidates

Mineralocorticoid receptor antagonists (MRAs) are highly effective 1, 3, 2:

• Spironolactone: 25-400 mg/day (usual dose 100-200 mg), most effective option 1, 4
• Eplerenone: Alternative if spironolactone not tolerated (less gynaecomastia/erectile dysfunction) 3
• Amiloride: 10-20 mg/day if MRAs not tolerated 4

Monitoring requirements 1:

• Potassium and creatinine levels, especially with concurrent ACE inhibitors or ARBs
• Renal function may worsen initially (unmasking underlying disease)

Medication Adjustments

Standard antihypertensives show only modest-to-moderate responses in primary aldosteronism 1. ACE inhibitors, ARBs, and calcium channel blockers are less effective than MRAs for blood pressure control in this condition.

Special Considerations

Genetic Testing

Consider genetic screening for glucocorticoid-remediable aldosteronism if 1:

• Family history of primary aldosteronism or stroke at young age (≤40 years)
• Onset of hypertension at ≤20 years with negative imaging
• All first-degree relatives of patients with familial hyperaldosteronism 2

Why This Matters for Outcomes

Primary aldosteronism causes aldosterone-specific cardiovascular and renal damage beyond hypertension alone 1, 5, 6. This includes:

• Relative hyperfiltration kidney injury exceeding essential hypertension
• Excess cardiovascular morbidity independent of blood pressure
• Higher rates of stroke, myocardial infarction, and atrial fibrillation

Targeted treatment (surgery or MRAs) specifically mitigates this aldosterone-mediated organ damage, improving cardiovascular and renal outcomes beyond what blood pressure reduction alone achieves 5, 6.

Common Pitfalls

• Don't delay: Primary aldosteronism diagnosed early has higher cure rates 3
• Don't skip AVS: Imaging alone is insufficient—adrenal lesions may be nonfunctional 1, 7
• Don't assume cure post-surgery: Significant proportion remain hypertensive and need continued management 1
• Don't ignore renal function: Both surgery and medical therapy can unmask underlying renal disease 1